This project develops novel inhaled antibacterial prototypes for multidrug-resistant pulmonary diseases, including tuberculosis, nontuberculous mycobacterial infections, and Gram-negative pathogens such as Pseudomonas aeruginosa. The PI with over 15 years of experience in antibacterial design will synthesize about 20-30 new derivatives using click-chemistry, based on cinnamamide, para-aminosalicylic acid, and hydroxy(aza)naphthanilide scaffolds with proven in-vitro activity. Inhalation delivery is chosen to maximize local lung exposure while reducing systemic toxicity, overcoming the limits of oral antibiotics. In partnership with the University of Vienna, candidates will undergo profiling (solubility, pKa/logP, cytotoxicity, permeability, epithelial retention) in Calu-3 models. The project will advance from TRL 2–3 to TRL 5, delivering validated sterile solutions for nebulization and paving the way for next-generation therapies with strong clinical and commercial potential.

Cíle udržitelného rozvoje

Masarykova univerzita se hlásí k cílům udržitelného rozvoje OSN, jejichž záměrem je do roku 2030 zlepšit podmínky a kvalitu života na naší planetě.